cGxP.wire https://validator.w3.org/feed/docs/rss2.html Annexon to Present Vonaprument Data From ARCHER II Marea Therapeutics and Lisata to Present MAR001 Phase 2b Data Milestone Enrolls First Canadian Patient in ReVeRA-301 Takeda Highlights Arcotatug and TAK-928 at ESMO 2026 Genentech Reports Positive Interim Phase 3 Sefaxersen Data TriSalus Gains FDA Clearance for TriNav Advance Travere Gains Notice of Allowance for FILSPARI FSGS Patent Sun Pharma Launches Taro-Methylphenidate ER for ADHD AC Immune Reports Positive Week-100 VacSYn Phase 2 Data ANI Gains FDA Approval for Everolimus Oral Suspension Tablets Ionis and Roche Report Positive Phase 3 IgAN Results Oruka Reports Positive Week 28 ORKA-001 Psoriasis Data Adagene Gains NMPA Clearance for ADG138 IND Wave Initiates Phase 2a WVE-007 Combination Trial for Obesity Fullspan Health Launches AIQ for Pharma AI Search Rhythm Gains Health Canada Approval for IMCIVREE in HO Artelo Files Patent for ART27.13 in Obesity Iterion Therapeutics Reports Positive Tegavivint Phase 1b Data Envisagenics and Boehringer Advance Precision Cancer Therapies Biocon Pertuzumab Biosimilar Gains EMA CHMP Recommendation Filana Gains FDA Lift of Simufilam Clinical Hold Ionis Reports Positive Phase 3 Ulefnersen Results Roche Wins EU Approval for Susvimo in Wet AMD Cordis Wins FDA Approval for SELUTION SLR Balloon Amgen Reports Positive Phase 3 Dazodalibep Results Vertex Reports Positive Inaxaplin Results in Kidney Disease Kazia Advances Paxalisib in Rare Seizure Disorders Johnson & Johnson Reports Positive CAPLYTA Phase 3 Data Viking Therapeutics Reports Positive VK2735 Weight Results Edgewise Advances EDG-7500 for Hypertrophic Cardiomyopathy IMUNON Advances IMNN-001 Phase 2 After Favorable Safety Review Quoin Gains FDA Fast Track for QRX003 in Peeling Skin Syndrome Palisade Bio Gains FDA IND Clearance for PALI-2108 Polyrizon Enrolls First Patient in NASARIX U.S. Study Traferox Gains FDA Clearance for X°Port Heart System AIM Highlights Ampligen Potential in Pancreatic Cancer MAIA Advances Phase 3 Ateganosine Trial in Advanced NSCLC Ophirex Publishes Phase 2 BRAVIO Varespladib Data Seek Labs Launches Open Impact Program for Neglected Diseases Zealand Pharma Initiates Phase 3 ZUPREME Program for Petrelintide Roche Reports Positive Phase 3 Sefaxersen Data in IgAN Applied Biologics Completes CAMPX Patient Follow-Up OSE to Present Phase 2 Tedopi Data in Metastatic NSCLC Corcept Gains Positive CHMP Opinion for Lifyorli in Ovarian Cancer Daiichi Sankyo and AstraZeneca Gain EU Backing for Enhertu SystImmune Advances SI-B037 Into Phase 1/1b Trial Mercy BioAnalytics Advances Evident Ovarian Cancer Test Beactica Advances BEA-17 Toward Glioblastoma Trials Kelun-Biotech to Present Sac-TMT Phase 3 Data at ESMO 2026 AbbVie Wins EU Approval for RINVOQ in Pediatric JIA